Orforglipron (Foundayo) Cost: Price With & Without Insurance, and Cheaper GLP-1 Options (2026)

Foundayo is the brand name for orforglipron, the first oral, non-peptide GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for chronic weight management from Eli Lilly. It is a once-daily tablet you can take any time of day, with or without food and with no water restriction, and it needs no refrigeration. The cost question has two very different answers depending on your coverage: with commercial insurance and the LillyDirect savings card, Foundayo starts at about $25 per month; paying cash without insurance, it runs roughly $149 to $349 per month through LillyDirect, scaled by dose tier. Because Foundayo is a brand-only, on-patent drug, there is no compounded or generic orforglipron at any price. This guide walks the real numbers, the Medicare and Medicaid exclusion from the savings card, why no cheaper version of orforglipron exists, and how the price compares to compounded semaglutide and tirzepatide — which are cheaper but injectable and a different molecule entirely. This is general information, not medical advice.

How much does Foundayo (orforglipron) cost?

Foundayo's cost splits cleanly along one line: whether you have commercial insurance. With commercial (employer or marketplace) insurance and the LillyDirect savings card, Foundayo starts at about $25 per month. Paying cash with no insurance, the self-pay price runs roughly $149 to $349 per month through LillyDirect, scaled by which dose you are on. ^{[1] [3]} There is no compounded or generic orforglipron, so these manufacturer channels are effectively the price floor for the molecule — there is no cheaper way to get orforglipron itself.

The headline self-pay schedule on LillyDirect is dose-tiered, climbing as your maintenance dose climbs:

For the practical mechanics of starting Foundayo, including the once-daily no-food, no-water-restriction dosing and the titration schedule, see our companion guide on how to take Foundayo, and our breakdown of where to get orforglipron for the LillyDirect enrollment and prescriber routing.

Foundayo cost with commercial insurance ($25/month)

If you have commercial insurance — an employer-sponsored plan or a plan you bought through the marketplace — the LillyDirect savings card brings Foundayo to a starting price of about $25 per month. ^[3] That figure assumes your commercial plan provides some level of coverage for the drug; the savings card reduces what you pay out of pocket on top of whatever your plan adjudicates. As with all manufacturer copay programs, the exact amount you pay can depend on your specific plan's formulary placement, prior-authorization status, and benefit design.

Foundayo cost without insurance (self-pay $149–$349)

Without insurance — or if your plan declines to cover Foundayo for weight management — you can buy it through LillyDirect Self Pay at a dose-tiered cash price. The schedule runs roughly $149, $199, $299, and $349 per month as you move up the dose ladder, with the top $349 tier available for $299 through an automatic purchase offer. ^[3] The lower tiers correspond to the starting and titration doses; the higher tiers correspond to the maintenance dose, which for Foundayo is 17.2 mg once daily.

Self-pay does not require insurance verification, and because Foundayo is an oral tablet, there is no cold-chain shipping, no refrigeration, and no injection supplies to budget for — it ships and stores like an ordinary prescription pill. A prescription is still required; LillyDirect routes through partnered telehealth clinicians if you do not already have a treating prescriber.

Why there is no compounded or generic orforglipron

One of the most common cost questions about a new GLP-1 is whether a cheaper compounded or generic version exists. For orforglipron, the answer is no, and will be no for years. Foundayo is a brand-only, on-patent drug that Eli Lilly launched in 2026. Several structural reasons rule out a cheaper copy:

• No generic. Generic approval requires the originator's patents and regulatory exclusivity to expire. Orforglipron is a newly approved, on-patent small molecule, so no generic can be approved for the better part of a decade.
• No compounded version. Compounding pharmacies are only permitted to compound copies of a drug under narrow circumstances — most commonly when the FDA-approved product is on the official drug shortage list. Orforglipron has never been in shortage, and as a freshly launched branded product it is not eligible for routine commercial compounding.
• It is a complex small molecule, not a peptide. Unlike injectable semaglutide and tirzepatide (peptides that grey-market vendors synthesize), orforglipron is a non-peptide small molecule whose manufacturing is proprietary to Lilly. There is no established research-chemical supply chain for it.

The practical upshot: if you specifically want oral orforglipron, the LillyDirect prices above are the floor — there is no legitimate cheaper source for the molecule itself. The cheaper GLP-1 options are different drugs (compounded semaglutide or tirzepatide), which we compare next.

Cheaper GLP-1 options: compounded semaglutide and tirzepatide

If your priority is the lowest monthly cost rather than the oral-pill format specifically, the cheapest legitimate GLP-1 options are compounded semaglutide and compounded tirzepatide from telehealth providers, which our vetted partners run in the roughly $99 to $199 per month range. That undercuts even the lowest Foundayo self-pay tier. But there are two important trade-offs that make this a genuine apples-to-oranges comparison:

• Different molecule. Compounded semaglutide and tirzepatide are not orforglipron. They are peptide GLP-1 (and, for tirzepatide, GIP/GLP-1) agonists with their own clinical profiles. Tirzepatide in particular produces larger average weight loss than orforglipron did in its trials; semaglutide is broadly comparable in magnitude.
• Injectable, not oral. Compounded GLP-1 is a once-weekly subcutaneous injection, not a daily pill. If your whole reason for choosing Foundayo is that you want to avoid needles, compounded GLP-1 does not solve that.
• Regulatory caveat. Compounded GLP-1 sits outside the FDA enforcement-discretion framework that lapsed in 2025; legitimate providers dispense pharmaceutical-grade product from licensed pharmacies, but the broad-commercial-compounding legal status is unsettled. See our oral vs injectable GLP-1 guide for the full trade-off.

Here is how Foundayo's cost sits against the cheaper compounded options and the brand injectables (Wegovy and Zepbound), so you can see exactly what you are paying for at each tier:

The honest framing: oral pill vs lowest cost

The decision comes down to what you are optimizing for, and being honest about the trade-off matters more here than the raw numbers:

• If you specifically want the oral pill — no needles, no weekly injection, no cold chain — then Foundayo is your option, and it is brand-only. Your cheapest legitimate path is $25/month with commercial insurance and the savings card, or $149-$349/month self-pay by dose. There is no compounded or generic shortcut for orforglipron.
• If cost is the priority and you are open to an injectable, compounded semaglutide or tirzepatide from a vetted telehealth provider is cheaper (roughly $99-$199/month) — but it is a different molecule delivered by weekly injection, with the regulatory caveat noted above. The savings are real, but you are switching products, not getting a cheaper version of Foundayo.
• If you have commercial insurance, the math often favors Foundayo outright: $25/month with the savings card can beat even the cheapest compounded option, with the convenience of an FDA-approved oral pill and no compounding-legality question.

If you would consider switching to a cheaper compounded GLP-1 injectable, here are the top vetted providers by our editorial score. This list is for readers who have read the trade-off above and actively choose the cheaper injectable route — Foundayo remains the only oral non-peptide option and is brand-only.

Foundayo vs Rybelsus: two different oral options

Foundayo is not the only oral GLP-1 on the market — Rybelsus (oral semaglutide) has been available since 2019. The two are genuinely different: Rybelsus is an oral peptide that requires a strict empty-stomach, water-only, 30-minute fasting protocol to absorb, while Foundayo is a non-peptide small molecule taken any time of day with or without food and no water restriction. They also differ on indication, dose, and cost. For a full side-by-side, see orforglipron vs Rybelsus.

What you actually get for the price (ATTAIN-1 results)

Cost is only half the picture; the other half is how much weight loss the price buys. In the ATTAIN-1 phase 3 obesity trial, orforglipron at the labeled maintenance dose produced approximately 11.1 percent mean weight loss. ^[2] That is comparable to early-generation semaglutide and below the magnitude seen with tirzepatide in the SURMOUNT trials. In short: Foundayo delivers solid, oral, FDA-approved weight loss in the same neighborhood as injectable semaglutide, with the convenience of a daily pill and no needles — and the price you pay reflects that brand, on-patent, oral-format premium. The orforglipron molecule's once-daily oral dosing without a food-timing restriction is supported by its published pharmacokinetic profile. ^[4]

Bottom line

• With commercial insurance and the LillyDirect savings card, Foundayo starts at about $25 per month. Medicare and Medicaid beneficiaries are not eligible for that price.
• Without insurance, the LillyDirect Self Pay price is dose-tiered at roughly $149, $199, $299, and $349 per month, with the top tier available at $299 via an automatic purchase offer.
• There is no compounded or generic orforglipron. Foundayo is brand-only and on-patent; the LillyDirect channels are the floor for the molecule.
• Cheaper GLP-1 options exist but are different drugs. Compounded semaglutide and tirzepatide run roughly $99-$199/month, but they are injectable peptides, not oral orforglipron, and carry a regulatory caveat.
• The honest choice: if you specifically want the oral pill, Foundayo is brand-only; if cost is the priority and you are open to an injectable, compounded GLP-1 is cheaper.

Frequently asked questions

Pricing verification. Foundayo commercial-insurance starting price of $25/month (Medicare and Medicaid excluded) and the dose-tiered self-pay schedule of approximately $149/$199/$299/$349 per month (top tier available at $299 via an automatic purchase offer) per LillyDirect's listed Foundayo pricing. FDA approval date (April 1, 2026), the once-daily oral non-peptide profile, and the ATTAIN-1 weight-loss magnitude per Eli Lilly's announcements. PMID 38402332 (orforglipron food-effect pharmacokinetics, Ma X et al., Diabetes Ther 2024) verified live via PubMed E-utilities esummary. Compounded semaglutide and tirzepatide ranges reflect our vetted-provider pricing and change frequently.

Important disclaimer. This article is general educational information only — not medical advice, not legal advice, and not a substitute for consultation with a licensed prescriber. GLP-1 pricing and coverage are a YMYL (Your Money or Your Life) topic. Prices change; verify the current Foundayo cost on LillyDirect and confirm coverage with your insurer before enrolling. Weight Loss Rankings does not prescribe, dispense, or endorse any specific compounding pharmacy or product.